T Cell News and Research

Latest T Cell News and Research

Research reveals how cancers shield themselves from immune attack

Melanoma, if not detected in its early stages, transforms into a highly deadly, treatment-resistant cancer. Although the immune system initially responds to melanoma and mounts anti-tumor attacks, these assaults are generally ineffective, allowing more advanced melanomas to win the battle and spread beyond the primary site.

13 Jan 2010

Blood test may be effective for diagnosing lung cancer

Of the nearly 150,000 abnormal chest X-rays performed each year in the United States, 25 percent of patients will display only benign lung pathologies on further surgical examination.

13 Jan 2010

GIND scientists identify major role of TDP-43 in two neurodegenerative diseases

Scientists at the Gladstone Institute of Neurological Disease (GIND) have identified the reason a key protein plays a major role in two neurodegenerative diseases.

13 Jan 2010

NIH awards 12 research grants totaling $5 million for Tβ4 research

REGENERX BIOPHARMACEUTICALS, INC. announced today that National Institutes of Health (NIH) has awarded 12 research grants totaling over $5,000,000 for the study of Tβ4 in 2009/2010. Many of these grants will be going to collaborators with whom RegeneRx is working to understand its numerous biological activities and capabilities in medical indications, including the role of Tβ4 as an anti-inflammatory agent in tissue regeneration and its promotion of stem cell maturation.

13 Jan 2010

Scientists discover new protein function that helps control cell behavior

Carnegie Mellon University's Philip R. LeDuc and his collaborators in Massachusetts and Taiwan have discovered a new function of a protein that could ultimately unlock the mystery of how these workhorses of the body play a central role in the mechanics of biological processes in people.

13 Jan 2010

Bevacizumab drug shows promise to slow tumor growth in lung cancer patients

Phase II study results of the agent ASA404 showed promise in patients with either squamous or non-squamous non-small cell lung cancer (NSCLC).

13 Jan 2010

TD2 and COTI work together to obtain approval of clinical trials for COTI-2

TGen Drug Development (TD2) and Critical Outcome Technologies Inc. (COTI) (TSXV:COT) announced today that they will work together to obtain approval of clinical trials for a promising new anti-cancer drug called COTI-2.

12 Jan 2010

Pall acquires U.S. biotechnology company

Pall Corporation, a global leader in filtration, separation and purification, today announced its acquisition of MicroReactor Technologies, Inc. (MRT), a privately held U.S. biotechnology company. MRT has developed a reliable, easy-to-use and cost-effective miniature bioreactor technology platform.

From Pall Corporation 12 Jan 2010

AMA awards unique CPT code for Cylex' ImmuKnow assay

Cylex Incorporated® announced today that the American Medical Association (AMA) CPT Editorial Panel approved the creation of new CPT coding based on the uniqueness, clinical value and widespread use of ImmuKnow, and the fact that existing CPT codes insufficiently captured all steps and costs of testing.

12 Jan 2010

Abraxis Bioscience awards John Wayne Cancer Institute $1M grant for identifying new cancer biomarkers

A $1 million grant from Abraxis Bioscience, Inc. to a world-famous research laboratory at John Wayne Cancer Institute at Saint John’s Health Center could help save lives of cancer patients by helping doctors more rapidly assess whether a treatment is working or not.

12 Jan 2010

Omnia Biologics and Biotech Experts announce deal for manufacturing and process development services

Biologics contract manufacturer Omnia Biologics, Inc. (Omnia) (Rockville, MD) and biologics manufacturing and process development consultants Biotech Experts, Inc. (Clarksburg, MD) today announced a deal for manufacturing and process development services.

12 Jan 2010

Older patients with acute myeloid leukemia may benefit from decitabine drug

Older patients with acute myeloid leukemia (AML) might benefit from a drug that reactivates genes that cancer cells turn off, according to research at Washington University School of Medicine in St. Louis and collaborating institutions.

12 Jan 2010

Evidence-based care for lung cancer patients results in an average cost savings of 35%, says study

A study recently conducted by US Oncology and Aetna finds that evidence-based care for patients with non-small cell lung cancer (NSCLC) results in an average cost savings of 35 percent over 12 months while demonstrating equivalent health outcomes. The study, which compared patients treated with evidence-based guidelines (also known as ‘on pathway’) to those treated with non-evidence-based guidelines (also known as ‘off pathway’), was published in the peer-reviewed Journal of Oncology Practice.

12 Jan 2010

Richard N. Zare to receive the 2010 TWR Medal for Conspicuous Achievement in Chemistry

Richard N. Zare, the Marguerite Blake Wilbur Professor in Natural Science at Stanford University has been selected to receive the 2010 Theodore William Richards (TWR) Medal for Conspicuous Achievement in Chemistry from the Northeastern Section of the American Chemical Society (NESACS).

12 Jan 2010

miRagen Therapeutics establishes SAB

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today the formation of the company’s world renowned Scientific Advisory Board (SAB). The SAB was established to provide miRagen with valuable guidance in developing an extensive pipeline of microRNA-based drugs and is comprised of leaders who are internationally recognized experts in their respective fields.

12 Jan 2010

Criminal prosecution on Salmonella outbreak is yet to begin

Over a year after the outbreak of Salmonella in peanut butter that sickened hundreds and caused the deaths of at least nine, criminal prosecution of the responsible parties has yet to begin.

12 Jan 2010

Cytheris commences enrollment in its recombinant human Interleukin-7 INSPIRE 2 program for HIV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 2, a Phase IIa clinical program evaluating the company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non Responders (INR) after at least 12 months of highly active anti-retroviral therapy (HAART).

12 Jan 2010

MedGenesis Therapeutix enters into license agreement with Amgen

MedGenesis Therapeutix Inc. ("MedGenesis"), a biopharmaceutical company developing and commercializing innovative treatments for patients with serious central nervous system (CNS) diseases, announced today that it has successfully entered into an agreement with Amgen Inc. ("Amgen"), granting MedGenesis an exclusive, worldwide license for glial cell line-derived neurotrophic factor (GDNF) protein in CNS and non-CNS indications, subject to the rights of a co-exclusive licensee for CNS indications in certain countries, as further described below.

12 Jan 2010

NanoViricides outlines its technology and current drug programs at Biotech Showcase conference

NanoViricides, Inc. (the "Company"), reports that the Company has been invited to present on January 12th at the Biotech Showcase™, a conference designed to showcase promising companies and technologies for partnering and investment purposes.

12 Jan 2010

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

Human Genome Sciences, Inc. today will announce its priority goals for 2010 and report on the Company’s increasing momentum toward commercialization of late-stage products for systemic lupus and chronic hepatitis C in a presentation by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 28th Annual JPMorgan Healthcare Conference in San Francisco.

12 Jan 2010

T Cell News and Research

Latest T Cell News and Research

Research reveals how cancers shield themselves from immune attack

Blood test may be effective for diagnosing lung cancer

GIND scientists identify major role of TDP-43 in two neurodegenerative diseases

NIH awards 12 research grants totaling $5 million for Tβ4 research

Scientists discover new protein function that helps control cell behavior

Bevacizumab drug shows promise to slow tumor growth in lung cancer patients

TD2 and COTI work together to obtain approval of clinical trials for COTI-2

Pall acquires U.S. biotechnology company

AMA awards unique CPT code for Cylex' ImmuKnow assay

Abraxis Bioscience awards John Wayne Cancer Institute $1M grant for identifying new cancer biomarkers

Omnia Biologics and Biotech Experts announce deal for manufacturing and process development services

Older patients with acute myeloid leukemia may benefit from decitabine drug

Evidence-based care for lung cancer patients results in an average cost savings of 35%, says study

Richard N. Zare to receive the 2010 TWR Medal for Conspicuous Achievement in Chemistry

miRagen Therapeutics establishes SAB

Criminal prosecution on Salmonella outbreak is yet to begin

Cytheris commences enrollment in its recombinant human Interleukin-7 INSPIRE 2 program for HIV

MedGenesis Therapeutix enters into license agreement with Amgen

NanoViricides outlines its technology and current drug programs at Biotech Showcase conference

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in